Institute of Neuropathology, University Medical Center – Eppendorf, Hamburg, Germany
“Investigating the Potential of the Neuroprotective N1 Fragment of the Prion Protein as a New Treatment Against Prion Diseases”
Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada
“Isolation and Strain-Specific Characterization of Pathogenic CJD Prion Particles”
Department of Biochemistry, Boston University School of Medicine
“Highly Synergistic Combination Therapy for Prion Diseases”
Rocky Mountain Laboratories, Montana
“Investigation of Prion Inactivation by Reactive Oxygen Species in Vivo”
Institute for Regenerative Medicine and Biotherapy, University of Montpellier, France
“Innovative Human 3D Neural Network Model for the Efficient Propagation of Human Prions”
Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, University of Texas-Houston Medical School
“Systematic Evaluation of the Zoonotic Potential of Different CWD Isolates”
Alzheimer's and Prion diseases Lab. at the Brain & Spine Institute (ICM) of the Salpêtrière Hospital, Sorbonne Université, Paris, France
Worms: A novel genetic model for therapeutic research in prion disease
Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, University of Texas-Houston Medical School
Design and Development of Anti-Prions as a Novel Therapeutic Strategy for Prion Disease
University of Verona, Italy
RT-QuIC assay on olfactory brushings in asymptomatic carriers of E200K mutation: An explorative study for establishing when a preventive therapy should be started
National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio
Assessing Prions in Sporadic CJD Patients
Institute of Neuropathology, University Medical Center Eppendorf
Targeting the endogenous proteolytic processing of PrPc as a therapeutic strategy against prion diseases
National Institute of Allergy and Infectious Diseases, National Institute of Health
Antisense Oligonucleotides to delay or prevent onset of prion disease in mice
Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
A new anti-prion compound that reduces PrPc levels and inhibits PrPsc replication. [Awaiting permission to release from Dr. Chiesa.]
Institute for Neurodegenerative Diseases, University of California, San Francisco
Human stem cell derived neural models for sCJD prion propagation and drug discovery
Department of Medicine, University of Alberta
Combination therapies for human prion disease
Center for Integrative Biology (CIBIO) at the University of Trento, Italy
Pharmacological Chaperones for the Cellular Prion Protein
CEA/DSV/iMETI/SEPIA (Institute for Emerging Illnesses and Innovative Therapies, Department of Prion and Atypical Infections Research), Fontenay-Aux-Roses, France
Human Mini-Brains as a New Platform to Identify and Validate Pharmaceutical Compounds for the Treatment of CJD
Prion Research Center, Colorado State University
The Role of Cellular Chaperones and the Unfolded Protein Response in Gerstmann-Sträussler-Scheinker Syndrome
University of California, San Diego
Mechanisms of Selective Neuronal Vulnerability in Human Prion Disease
National Prion Disease Pathology Surveillance Center, Case Western Reserve University School of Medicine Cleveland, Ohio
Developing Therapeutics for CJD Using Patient-Specific iPSC-Derived Neurons
